Anti-Human IGF-II R/IGF2R Reference Antibody (BI-1607, RUO) (HB103026)

Name: Anti-Human IGF-II R/IGF2R Reference Antibody (BI-1607, RUO)
Brand: abinScience
SKU: HB103026
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB103026
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	BI-1607
Expression system	Mammalian cells
Clonality	Monoclonal
Target	IGFR2, FCG2, Fc-gamma RII-b, CDw32, FcRII-b, IgG Fc receptor II-b, CD32, Fc-gamma-RIIb, Low affinity immunoglobulin gamma Fc region receptor II-b, FCGR2B
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P31994
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	BI-1607, BI1607, BI1607
Background	Low affinity immunoglobulin gamma Fc region receptor II-b (CD32b/FCGR2B) is a ~34 kDa protein. Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis.
References	1. Cortés J, et al. Abstract PO1-18-06: Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors–CONTRAST[J]. Cancer Research, 2024, 84(9_Supplement): PO1-18-06-PO1-18-06. [HB103026]
Note	For research use only. Not suitable for clinical or therapeutic use.